Le disease in peripheral blood or bone marrow even when incredibly sensitive immunophenotypic or molecular techniques are utilised to look for residual disease. These sufferers are considered to have achieved a minimal residual disease (MRD) adverse status.17-20 Various phase II trials have demonstrated that sufferers reaching MRD negativity possess a signif-icantly longer survival than individual